Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of “Hold” by Analysts

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have been assigned an average rating of “Hold” from the five ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $8.06.

A number of equities analysts have weighed in on RXRX shares. JPMorgan Chase & Co. dropped their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Wall Street Zen lowered Recursion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Morgan Stanley set a $5.30 price objective on Recursion Pharmaceuticals in a research report on Monday, August 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 40,000 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total transaction of $158,400.00. Following the completion of the sale, the director directly owned 6,218,287 shares of the company’s stock, valued at $24,624,416.52. This trade represents a 0.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $3.58, for a total transaction of $84,445.04. Following the completion of the transaction, the chief executive officer directly owned 2,175,796 shares in the company, valued at $7,789,349.68. This trade represents a 1.07% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 131,937 shares of company stock worth $478,874. 6.65% of the stock is owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. California State Teachers Retirement System lifted its position in shares of Recursion Pharmaceuticals by 257.8% in the second quarter. California State Teachers Retirement System now owns 2,055,919 shares of the company’s stock worth $7,545,000 after buying an additional 1,481,282 shares in the last quarter. Raiffeisen Bank International AG raised its holdings in shares of Recursion Pharmaceuticals by 6.2% during the 2nd quarter. Raiffeisen Bank International AG now owns 170,000 shares of the company’s stock worth $627,000 after acquiring an additional 10,000 shares in the last quarter. Syon Capital LLC raised its holdings in shares of Recursion Pharmaceuticals by 204.5% during the 2nd quarter. Syon Capital LLC now owns 33,399 shares of the company’s stock worth $123,000 after acquiring an additional 22,429 shares in the last quarter. Quantitative Investment Management LLC bought a new position in shares of Recursion Pharmaceuticals during the 2nd quarter valued at approximately $326,000. Finally, Wellington Management Group LLP boosted its position in shares of Recursion Pharmaceuticals by 19.3% during the 2nd quarter. Wellington Management Group LLP now owns 180,598 shares of the company’s stock valued at $663,000 after acquiring an additional 29,179 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Stock Performance

RXRX traded down $0.26 during midday trading on Monday, reaching $3.25. The company had a trading volume of 5,528,894 shares, compared to its average volume of 18,167,123. The business has a 50-day moving average of $3.30 and a two-hundred day moving average of $3.36. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals has a 1 year low of $2.77 and a 1 year high of $7.18. The company has a market cap of $1.74 billion, a P/E ratio of -3.11 and a beta of 1.03.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The company had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same quarter last year, the firm posted ($0.41) earnings per share. As a group, equities research analysts predict that Recursion Pharmaceuticals will post -0.92 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.